



UNITED STATES OF AMERICA
FEDERAL TRADE COMMISSION
WASHINGTON, D.C. 20580

Office of the Secretary

August 26, 2013

Mark L. Kovner, Esq.
Counsel For Barr Pharmaceuticals, Inc.
Kirkland & Ellis LLP
655 Fifteenth Street, N.W.
Washington, DC 20005

Re: *Shire Laboratories, Inc., et al., FTC File No. 061 0274*

Dear Mr. Kovner:

The Federal Trade Commission's Bureau of Competition has been conducting a nonpublic investigation to determine whether Shire Laboratories, Inc. (and its affiliates Shire plc, Shire LLC, and Shire Development Inc.), Barr Pharmaceuticals, Inc. (and its affiliates Barr Laboratories, Inc., Barr Distribution, Inc., Duramed Pharmaceuticals, Inc., Duramed Research, and Women's Capital Corporation), and Impax Laboratories, Inc., or others, have engaged in any unfair methods of competition that violate Section 5 of the Federal Trade Commission Act, 15 U.S.C. Sec. 45, as amended, by entering into agreements regarding or relating to Adderall XR and generic alternatives to Adderall XR, or other products for the treatment of attention deficit hyperactivity disorder (ADHD) and other conditions.

Upon further review of this matter, it now appears that no further action is warranted by the Commission at this time. Accordingly, the investigation has been closed. The action is not to be construed as a determination that a violation may not have occurred, just as the pendency of an investigation should not be construed as a determination that violation has occurred. The Commission reserves the right to take such further action as the public interest may require.

By direction of the Commission.

Donald S. Clark
Secretary